Novo Nordisk (NVO) said Friday the US Food and Drug Administration accepted its new drug application filing for an investigational 25 mg oral formulation of its obesity management drug Wegovy.
The FDA application for the oral Glucagon-like peptide-1 treatment is based on the results of a phase 3 trial, according to a statement.
The FDA will make a final decision on the application in Q4, the company said.
Wegovy injection 2.4 mg is currently approved for adults and children aged 12 years and older with obesity.
Shares were up 5.6% in recent trading.
Price: 69.18, Change: +3.58, Percent Change: +5.46
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.